Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker      Tax Corner NRI Centre Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Sun Phar 619.60 2.98
Hous Dev 1890.90 2.61
State Ba 292.70 0.68
Icici Ba 334.45 0.65
Axis Ban 623.85 0.90
Clear All Clear Last
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
FII Activity
Mutual Fund Activity
Results Watch
Results Calendar
Results Announced
IPO Watch
Recent News
Broker Research
Research Tutorial
Discussion Forum
Research Reports
Sector Watch
Economy Watch
Sun Pharmaceutical Industries Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs and Formulations
Market Lot: 1Face Value: 1ISIN Demat: INE044A01036
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

Business Profile
Sun Pharma (SUNPHARMA) is into specialty pharmaceuticals and active pharmaceutical ingredients. The company operates in select therapeutic segments like psychiatry, neurology, cardiology and gastroenterology. As many as eight bulk actives and 18 processes for DMFs have been developed and scaled up. In all, the company has received seven DMFs and nine EDMFs.

The company doubled its capacity and the area at the bulk active site in Panoli. With the completion of this expansion, 269,000 sq. ft. area has been added to the plant thereby offering additional 129 KL reactor capacity for the regulated markets.

The company plans to work on various technologies in NDDS and work on specific therapy areas for NCE. For products that are differentiated for the medium term, it would continue to work on technologically complex products such as liposome delivery systems, microspheres based delivery systems and controlled release technologies.

The company disclosed fall of 24.30% in consolidated net profit on y-o-y basis to Rs 13.09 billion, while total income fell 100.00% y-o-y basis to Rs 0.00 million for the quarter ended March 2018.

Recent Developments
Sun Pharmaceutical Industries has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration (FDA). CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Sun Pharmaceutical Industries announced that Sun Pharma has launched Kapspargo Sprinkle (metoprolol succinate) extended-release capsules in the US, for the treatment of hypertension (to lower blood pressure), angina pectoris (chest pain), and heart failure (to reduce the risk of cardiovascular mortality and heart-failure hospitalization in patients with heart failure).

Sun Pharmaceutical Industries today announced that one of its wholly owned subsidiaries has launched the generic versions of Glumetza (metformin hydrochloride) extended release tablets, 500 mg and 1000 mg in the US.

Sun Pharmaceutical Industries today announced that it has received approval from the U.S. Food and Drug Administration (USFDA) for INFUGEM??? (gemcitabine in 0.9% sodium chloride injection) 10 mg/mL, for intravenous use in a ready-to-administer (RTA) bag.

DUSA Pharmaceuticals, Inc., (DUSA) a wholly owned subsidiary of Sun Pharmaceutical Industries announced that DUSA has filed trade secret misappropriation and tortious interference claims in an ongoing patent infringement lawsuit against Biofrontera Inc., Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG in the United States District Court for the District of Massachusetts.

Sun Pharmaceutical Industries today announced that it has received the Establishment Inspection Report (EIR) from the US FDA for the inspection conducted at its Halol facility (Gujarat, India) during the period February 12-23, 2018.

Sun Pharmaceutical Industries announced a small rise in consolidated net profit for the quarter ended March 2018. During the quarter, the profit of the company rose 6.97% to Rs 13,089.60 million from Rs 12,237.10 million in the same quarter last year.

Sun Pharmaceutical Industries and Churchill Pharmaceuticals, LLC. (Churchill) announced that one of Sun Pharma???s wholly owned subsidiary companies has received approval from the U.S. Food and Drug Administration (FDA)

In Brief

Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited